



Your Impact in Action



Because of your support, we accomplish great things at Dana-Farber Cancer Institute. Highlights from 2024 include:



Revolutionary Science

New Therapy for Glioma

For the first time since 1999, the FDA has granted approval to a new drug to treat grade 2 gliomas with IDH1 or IDH2 mutations. The therapy, vorasidenib, was developed by Dana-Farber researchers and tested in a Dana-Farber-led phase 3 clinical trial.

Immunotherapy for Colorectal Cancer

In a phase 1 clinical trial, Dana-Farber researchers reported the first safe and effective use of immunotherapy for the most common subtype of colorectal cancer, with 73% of trial patients benefiting from the treatment.

Preventing Relapse

Dana-Farber researchers developed a method to spur CAR T cells to persist longer in the body, enabling them to spring back into action if cancer recurs. This revolutionary technique has the potential to eliminate relapse and create longer-lasting results for patients.

Uncovering Mechanisms of Resistance

Dana-Farber scientists discovered how non-small cell lung cancer tumors acquire resistance to immunotherapy, a common problem with this type of cancer. The findings lay the groundwork for personalized strategies to overcome, prevent, and possibly delay acquired resistance.

Easing Depression in Cancer Patients


In a companion study for one of the first clinical trials testing psychedelic-assisted therapy, Dana-Farber researchers found that for cancer patients who are suffering from major depression, treatment with psilocybin plus individual and group therapy can significantly relieve symptoms.

Breakthrough for Advanced Kidney Cancer

The FDA approved the use of belzutifan for adult patients with advanced renal cell carcinoma following a Dana-Farber-led clinical trial, in which patients were 25% less likely to have progressed compared to those taking the standard treatment.



Your Impact in Action



Extraordinary Care



World-class Care, Worldwide

Dana-Farber brought high quality, patient-centered care model to Brazil through the launch of the Oncoclínicas Cancer Center, a collaborative effort between Dana-Farber and Oncoclínicas & Co, the largest group dedicated to cancer in Latin America.

Intercepting Cancer at its Earliest Stages

Dana-Farber launched the Centers for Early Detection and Interception, a first-of-its-kind, integrated clinic to increase early detection of precancerous conditions and improve access to screening for historically marginalized communities.

Education Spurs Genetic Testing

A collaborative study co-led by Dana-Farber demonstrated that an online genetic education program can be a powerful motivator for people with a family history of cancer—90% of participants went on to undertake genetic testing to assess their cancer risk.

Caring for Firefighters

Through the Direct Connect Partnership, Dana-Farber is providing Massachusetts firefighters with streamlined, guided access to world-class cancer care, marking a crucial step in addressing the heightened cancer risk faced by these first responders.

Empowering Neurodivergent Patients

Launched in 2024, Dana-Farber's Neuro-Inclusive Oncology Care and Empowerment program provides specialized education and care to adults with intellectual and/or developmental disabilities, who often face complex barriers when accessing health care.



Exceptional Expertise

Top in New England, Top 4 Nationwide

Dana-Farber Cancer Institute has been the top-ranked cancer hospital in New England by *U.S. News & World Report* for 24 consecutive years, and is the only cancer center in the country ranked in the top 4 for both adult and pediatric cancer programs.

Supporting LGBTQ+ People

Dana-Farber was named a 2024 LGBTQ+ Healthcare Equality Leader by Human Rights Campaign. The Institute received the highest score based on how many LGBTQ+ inclusive policies and practices are in place to support our patients, visitors, and employees.

Top Doctors

Boston magazine named more than 125 physicians and surgeons affiliated with Dana-Farber Cancer Institute to its annual Top Doctors™ guide, recognizing their expert and compassionate care.

Nursing Excellence

In 2024, Dana-Farber earned Magnet® status from the American Nurses Credentialing Center for the fifth consecutive time. This gold standard for nursing is an honor granted to fewer than 10% of the nation's hospitals, and only 1% have achieved it five consecutive times.



“Dana-Farber is truly a remarkable organization and a global leader in innovation, and in caring and advocating for cancer patients.”

Benjamin L. Ebert, MD, PhD
President and CEO
Dana-Farber Cancer Institute

George P. Canellos, MD, and
Jean S. Canellos Professor of Medicine
Harvard Medical School

Find out more: Dana-Farber.org | JimmyFund.org | DefyCancer.org

